Enclomiphene Citrate: What the Research Actually Shows

Introduction to Enclomiphene

Enclomiphene citrate is a selective estrogen receptor modulator that blocks estrogen feedback at the hypothalamus and pituitary, prompting your body to release more luteinizing hormone and follicle-stimulating hormone. Those hormones signal the testes to produce testosterone and sperm. The mechanism differs from testosterone replacement therapy, which shuts down your own production and usually stops sperm output.

The compound is the trans isomer of clomiphene citrate, which has been used off-label in men for decades. Clomiphene is a 62:38 mix of enclomiphene and zuclomiphene; zuclomiphene has a longer half-life and is thought to account for some of clomiphene's side effects. Isolating enclomiphene was intended to preserve the testosterone-raising effect while reducing adverse events. Initial results support that hypothesis, but the trial populations were small and the follow-up periods short.

When discussing enclomiphene, it is crucial to understand the nuances of the research and its regulatory status. One cited trial enrolled overweight men with secondary hypogonadism, rather than a broader population, which limits the generalizability of its results. This detail is essential for accurately interpreting the study's findings. Additionally, the regulatory landscape for enclomiphene is complex; while some clinics may market it for various uses, it is important to contrast these claims with what the FDA labels and guidelines actually say.

This guide walks through what the human trials measured, what they did not measure, and what you need to know about regulatory status, cost and monitoring before signing up with a clinic. For a broader look at non-pharmaceutical approaches, see Boron and Testosterone: What the Small Studies Found.

Explore the research on enclomiphene citrate, its mechanisms, human trials, and regulatory status to understand its impact on testosterone levels.

How Does Enclomiphene Citrate Work?

Enclomiphene citrate is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors in the hypothalamus and pituitary gland, which are part of the hormonal feedback loop that regulates testosterone production. When estrogen receptors in these areas are blocked, the brain reads lower estrogen activity and responds by increasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH signals the testes to produce more testosterone; FSH drives sperm production.

This is the same mechanism used by clomiphene citrate, the mixed-isomer drug that has been prescribed off-label for secondary hypogonadism for years. Clomiphene is a 50/50 mixture of two isomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer). Enclomiphene is the active component that blocks estrogen receptors and raises LH. Zuclomiphene has a much longer half-life and weaker activity, and it is thought to contribute more to side effects without adding therapeutic benefit.

Enclomiphene Versus Clomiphene

Enclomiphene citrate was developed as a purified form of the active isomer, removing zuclomiphene from the formulation. The idea was to preserve the testosterone-raising effect while reducing the side-effect burden and drug accumulation that comes with zuclomiphene's slow clearance. Animal studies suggested that enclomiphene could increase circulating testosterone levels by acting on the hypothalamic-pituitary-gonadal axis without the long half-life complications.

In practice, both drugs raise testosterone by the same route: blocking estrogen feedback, which lifts LH, which signals the testes. The difference is in the pharmacokinetics and the presence or absence of the inactive isomer. Enclomiphene clears faster and does not carry zuclomiphene along for the ride.

Comparison With Other SERMs

Other SERMs, such as tamoxifen and raloxifene, also block estrogen receptors but are used for different indications and have different tissue selectivity profiles. Tamoxifen is used primarily in breast cancer treatment and prevention. Raloxifene is used for osteoporosis in postmenopausal women. Neither is commonly used to raise testosterone in men, and neither has the same pharmacokinetic profile or approval pathway as enclomiphene or clomiphene.

The key takeaway: enclomiphene works by blocking estrogen receptors in the brain, which removes the brake on LH and FSH production. The testes respond by making more testosterone and sperm. It is the purified active isomer of clomiphene, designed to do the same job with a cleaner pharmacokinetic profile.

Summary of Human Trials

The published trials on enclomiphene are small and short. The largest study comparing enclomiphene directly to clomiphene enrolled 66 patients total—33 per group—and tracked them for a median duration that the paper does not specify beyond "longitudinal." That is the entire head-to-head dataset.

In that 66-patient cohort, enclomiphene raised testosterone by a median of 166 ng/dL from baseline, compared to 98 ng/dL for clomiphene. The difference was not statistically significant (P = 0.20), meaning the study could not rule out chance. Both groups started with hypogonadism; neither paper reports the baseline testosterone, age range, or BMI distribution, so you cannot tell who was actually studied beyond "hypogonadal men."

Adverse Effects Were Less Common with Enclomiphene

The same 66-patient trial found that 47% of clomiphene recipients reported adverse effects, versus 13.8% of enclomiphene recipients (P = 0.001). The most common complaints were decreased libido (33.3% clomiphene, 8.6% enclomiphene; P = 0.001), reduced energy (P = 0.044), and mood changes (P = 0.03). Estradiol dropped slightly with enclomiphene (median change –5.92 pg/mL) and rose with clomiphene (+17.50 pg/mL, P = 0.001).

Those are real differences, but they come from a single small study. The authors call for "more extensive studies" to validate the conclusions, and they are right to do so.

What the Trials Did Not Measure

No published trial has compared enclomiphene to testosterone replacement therapy head-to-head. No trial has followed patients beyond a few months. No trial has enrolled men with normal baseline testosterone or men over 65. The studies measure total testosterone and estradiol; they do not consistently report free testosterone, SHBG, LH, FSH, hematocrit, or PSA—the full panel you need to monitor safely.

For a deeper look at how other supplements stack up in small trials, see Boron and Testosterone: What the Small Studies Found.

Long-term Use and Unknowns

The trials that tested enclomiphene ran for weeks or months, not years. The longest published data tracked men for six months. What happens beyond that is not documented in the peer-reviewed literature.

Short-term safety data show fewer adverse effects with enclomiphene than with clomiphene citrate. In one comparative study, adverse effects were reported in 13.8% of men on enclomiphene versus 47% on clomiphene (P=0.001). Decreased libido occurred in 8.6% of enclomiphene users compared to 33.3% on clomiphene (P=0.001). Mood changes appeared in 9.1% of the clomiphene group and 0% of the enclomiphene group (P=0.03).

What We Don't Know Yet

No published trial has followed men on enclomiphene for more than six months. That leaves several questions open:

• Does the testosterone increase hold steady past the first year, or does the body adapt and the effect fade?
• Do adverse effects emerge with longer use that short trials did not capture?
• What happens to bone density, cardiovascular markers, and sperm counts after years of treatment?
• How does enclomiphene interact with other medications or conditions over time?

One review noted that enclomiphene should undergo placebo-controlled, randomized clinical trials for secondary hypogonadism associated with obesity, metabolic syndrome, and possibly infertility. Those trials have not been completed.

Monitoring Gaps

Because the long-term data do not exist, clinicians who prescribe enclomiphene off-label are working without a roadmap for what to monitor beyond the first few months. Standard practice borrows from clomiphene protocols: periodic testosterone, estradiol, LH, and lipid panels. Whether that captures everything relevant to multi-year use is unknown.

If you are considering enclomiphene for more than a few months, ask your prescriber what the monitoring plan looks like and how often labs will be drawn. The absence of long-term data means you and your doctor are making decisions in a gray zone. For context on how other supplements stack up in terms of evidence, see Boron and Testosterone: What the Small Studies Found.

Regulatory Status

Enclomiphene citrate has not been approved by the FDA for any use. The compound was evaluated for inclusion on the FDA's 503A Bulks List — a registry of substances that compounding pharmacies can use to prepare custom formulations — but as of 2021, development of enclomiphene as a drug has been discontinued for all medical purposes.

The FDA evaluated enclomiphene citrate for use in increasing serum testosterone, LH, and FSH to normal levels. Despite this evaluation, it did not receive approval as a standalone drug, and it remains unavailable as an FDA-approved prescription medication.

What This Means for Availability

Some telehealth clinics and compounding pharmacies offer enclomiphene citrate as a compounded medication under section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded drugs are not FDA-approved; they are prepared by licensed pharmacies for individual patients, typically when a physician prescribes a formulation that is not commercially available.

Because enclomiphene is unapproved, it is on the Department of Defense Prohibited List and falls under Section 4 of the WADA Prohibited List. This regulatory status means it is banned for use by service members and competitive athletes, regardless of how it is marketed or prescribed.

What the FDA Label Says

The FDA's evaluation document notes that enclomiphene citrate is slightly soluble in water, meaning particle size and polymorphism of the drug substance may be critical for solid oral dosage forms. The impurity profile is expected to be similar to clomiphene citrate, with likely impurities including residual cisclomiphene citrate.

This is where the gap between marketing and regulatory reality becomes visible. Clinics may emphasize convenience and results, but the FDA evaluation emphasizes formulation challenges and the absence of an approved product. If you are considering enclomiphene, ask your prescriber whether the formulation comes from a 503A-registered compounding pharmacy and whether they monitor for the impurities the FDA identified.

For a broader look at testosterone-related interventions and how supplement evidence compares to prescription options, see our guide on boron and testosterone.

Who Should Consider Enclomiphene?

Enclomiphene is not a first-line option for everyone with low testosterone. The published trials enrolled specific populations, and the regulatory guidance for clomiphene citrate (the racemic mixture from which enclomiphene is derived) emphasizes careful candidate selection and supervision by physicians experienced in endocrine disorders.

Men Who Want to Preserve Fertility

The strongest case for enclomiphene is in men with testosterone deficiency who cannot use traditional testosterone replacement therapy. The mechanism—raising LH and FSH to stimulate the testes—means it typically maintains or improves semen parameters rather than suppressing them. If you are planning to have children or want to keep that option open, this is the number that matters.

Traditional TRT usually shuts down sperm production within months. Enclomiphene works in the opposite direction, which is why the research highlights its role for men in whom testosterone therapy would compromise fertility.

Who Was Actually Studied

The trials enrolled men with secondary hypogonadism—low testosterone caused by insufficient signaling from the pituitary, not primary testicular failure. One frequently cited trial specifically enrolled overweight men with this condition. That population detail limits how broadly you can apply the results.

If your LH is already high and your testes are not responding, enclomiphene will not help. It works by asking the pituitary to send more signal; if the testes cannot hear the signal, more volume does not fix the problem. Test first, test twice: you need morning total testosterone, free testosterone, LH and FSH before anyone can tell you whether this mechanism fits your case.

Supervision and Monitoring

The label for clomiphene citrate states that workup and treatment should be supervised by physicians experienced in managing endocrine disorders. This is not a drug you order online and monitor yourself. The trials tracked testosterone, LH, FSH, estradiol, hematocrit and liver enzymes at regular intervals. Nobody selling it will tell you this up front, but those lab panels cost money and require physician interpretation.

Before signing up with a telehealth clinic, ask what the monitoring schedule looks like, who reads the labs, and what it costs you in money and time. The free option is to work with an endocrinologist or urologist who already manages hypogonadism and can bill your insurance for the visits and labs.

When to Look Elsewhere

If fertility is not a concern and your primary goal is the most reliable increase in testosterone, traditional TRT typically delivers more consistent results. The enclomiphene trials showed increases in total testosterone, but the response varied between individuals. Some men do not respond well, and the mechanism requires intact pituitary and testicular function.

If your baseline LH is low and your testes are healthy, enclomiphene may work. If your LH is already elevated, or if you have primary hypogonadism, it will not. If you are already on TRT and want to switch to preserve fertility, that is a different conversation—one that requires stopping TRT, waiting for your axis to recover, and then starting enclomiphene under close supervision. That transition is not simple and not always successful.

The ability to treat testosterone deficiency while maintaining fertility supports a role for enclomiphene in men in whom testosterone therapy would compromise reproductive goals.

Consultation Recommendations

Ask your doctor for a full hormone panel before choosing between enclomiphene and TRT. That panel should include total testosterone, free testosterone, SHBG, LH, FSH, estradiol, hematocrit and PSA if you are over 40. Two morning results, not one. One morning result is not a diagnosis.

If you are considering a telehealth clinic, ask how they handle non-responders, what the refund or transition policy looks like, and whether they provide records you can take to another provider if you switch. Worth knowing before you sign up: some clinics structure treatment as a monthly subscription with automatic billing, and the terms for pausing or stopping are not always clear until you try to cancel.

For a broader look at non-medication factors that affect testosterone—weight, sleep apnea, alcohol, training volume—see Boron and Testosterone: What the Small Studies Found, which covers supplement evidence graded by the size and quality of the human trials behind each ingredient.

Conclusion

Enclomiphene citrate raises testosterone by blocking estrogen feedback at the pituitary, which signals the body to produce more LH and FSH. The human trials show a median testosterone increase of 166 ng/dL, with lower estradiol changes and fewer reported adverse effects than clomiphene — specifically reduced rates of decreased libido, low energy, and mood changes. These results come from small, short-duration studies in men with secondary hypogonadism, not from the general population or from trials lasting more than a few months.

The regulatory landscape matters. Enclomiphene does not have FDA approval for testosterone therapy. Clinics prescribing it do so off-label, often through compounding pharmacies. What the FDA labels and guidelines actually say about monitoring, contraindications, and approved indications often differs from what appears in clinic marketing. Before choosing enclomiphene, ask your doctor for two morning testosterone results, LH, FSH, and a full panel. One result is not a diagnosis, and the treatment choice depends on whether your pituitary is still responding.

Long-term data — beyond six months, in diverse populations, with fertility and cardiovascular endpoints tracked — does not yet exist in the published record. The studies we have are small and industry-funded. Further research is warranted to validate these conclusions and establish what happens after the first year. Until then, the evidence supports enclomiphene as a treatment option for hypogonadal men who want to preserve fertility and avoid exogenous testosterone, but it does not support claims of universal safety or long-term efficacy.

If you are comparing treatment paths, the research on related interventions — such as boron supplementation — also comes from small trials with limited follow-up. The pattern is the same: promising short-term signals, gaps in the long-term record, and marketing that runs ahead of the data. Test first, test twice, and read the label before you sign up.

FAQ

What is enclomiphene citrate used for?

Enclomiphene citrate is studied for raising testosterone in men with secondary hypogonadism while preserving fertility. It blocks estrogen receptors in the brain, prompting the body to release more LH and FSH, which signal the testes to produce testosterone and sperm. The FDA has not approved it for any indication; it is available only through compounding pharmacies.

How does enclomiphene citrate differ from clomiphene?

Enclomiphene citrate is the purified trans-isomer of clomiphene citrate. Clomiphene is a 62:38 mixture of enclomiphene and zuclomiphene; zuclomiphene has a longer half-life and contributes to side effects without adding therapeutic benefit. Enclomiphene was developed to preserve the testosterone-raising effect while reducing adverse events.

What are the side effects of enclomiphene citrate?

In a 66-patient trial, 13.8% of enclomiphene users reported adverse effects, compared to 47% on clomiphene. The most common side effects with enclomiphene were decreased libido (8.6%), reduced energy, and mood changes. Estradiol dropped slightly with enclomiphene, whereas it rose with clomiphene.

Is enclomiphene citrate FDA-approved?

No. Enclomiphene citrate has not been approved by the FDA for any indication. It is available only through compounding pharmacies under section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded drugs are not subject to the same manufacturing, quality control, or efficacy standards as FDA-approved medications.

Who should consider enclomiphene citrate?

Men with secondary hypogonadism who want to preserve fertility are the strongest candidates. Enclomiphene raises LH and FSH to stimulate natural testosterone and sperm production, unlike testosterone replacement therapy, which shuts down both. It does not work for primary testicular failure, where the testes themselves are unresponsive.

How long can you take enclomiphene citrate?

The longest published trial tracked men for six months. No data exist on safety or efficacy beyond that period. Clinicians prescribing enclomiphene off-label are working without long-term evidence, borrowing monitoring protocols from clomiphene studies.